## **Open Pharma quarterly update: April–June 2021**

We've had a great spring here at Open Pharma, with two new Supporters and plenty of fresh ideas.


We kicked off this quarter with the 17th Annual Meeting of ISMPP in April, at which we presented two posters about the use of ORCID iDs in pharma publications and one about open access benchmarking. All three posters are available on our figshare page. In addition, we took part in three roundtable sessions at the meeting.

April also saw our second Roundtable Meeting of the year. This virtual meeting brought our Members and Supporters together with publishers to discuss whether and how transformative agreements could work for pharma.

In June, we submitted our recommendations for PLSs to *Current Medical Research and Opinion*. Thank you to all of the authors and reviewers for their input and hard work.

Finally, we had two stimulating topic meetings this quarter: in May, we heard two new project proposals, and in June, we discussed how to increase the use of ORCID in pharma-funded publications.

## Activities this quarter



## Coming up

We have three topic meetings planned for the coming quarter – look out for more details over the summer!

We will also increase our blog activities and gain fresh perspectives by inviting more guest authors to write for us.

Oxford PharmaGenesis takes part in a number of activities revolving around open science to help Open Pharma gather insight and build a strong network of supporters; these activities go beyond the core Open Pharma plan and are carried out at no cost to Open Pharma.

CMRO, Current Medical Research and Opinion; EMWA, European Medical Writers Association; GP, general practitioner; ISMPP, International Society for Medical Publication Professionals; ORCID, Open Researcher and Contributor ID; PLS, plain language summary